免疫检查点对慢性HBV感染者自然杀伤细胞功能的影响

黄俊; 邵慧娟; 马学锋; 于晓辉; 郑晓凤; 张久聪

doi:10.3969/j.issn.1001-5256.2023.08.025

免疫检查点对慢性HBV感染者自然杀伤细胞功能的影响

DOI: 10.3969/j.issn.1001-5256.2023.08.025

黄俊^{1, 2},
邵慧娟^{1, 2},
马学锋^{1, 2},
于晓辉²,
郑晓凤^3, , ,,
张久聪^2, , ,

1.
甘肃中医药大学第一临床医学院，兰州 730000
2.
中国人民解放军联勤保障部队第九四〇医院消化内科，兰州 730050
3.
兰州大学第二医院消化内科，兰州 730030

基金项目:

甘肃省非感染性肝病临床研究中心项目 (21JR7RA017);

中央高校优秀青年团队培育项目 (31920220065);

第九四〇医院拔尖项目 (2021yxky02)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：黄俊完成论文的选题、写作及文献资料的分析；邵慧娟、马学锋参与文献资料的分析；郑晓凤、张久聪参与校稿；于晓辉、张久聪指导并修改论文。

详细信息

通信作者:
郑晓凤，zhengxf19892013@126.com (ORCID: 0009-0002-9660-1224)

张久聪，zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)

计量
- 文章访问数: 288
- HTML全文浏览量: 75
- PDF下载量: 44
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-01
- 录用日期: 2022-12-18
- 出版日期: 2023-08-20

Effect of immune checkpoint molecules on the function of natural killer cells in patients with chronic hepatitis B virus infection

Jun HUANG^{1, 2},
Huijuan SHAO^{1, 2},
Xuefeng MA^{1, 2},
Xiaohui YU²,
Xiaofeng ZHENG^{3
, ,
,},
Jiucong ZHANG^{2
, ,
,}

1.
The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730000, China
2.
Department of Gastroenterology, The 940 Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, China
3.
Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou 730030, China

Research funding:

Gansu Clinical Medical Research Center for Non-infectious Liver Diseases (21JR7RA017);

Project of Excellent Youth Team Training for the Central Universities (31920220065);

The Top Project of The 940 Hospital (2021yxky02)

More Information

Corresponding author: ZHENG Xiaofeng, zhengxf19892013@126.com (ORCID: 0009-0002-9660-1224); ZHANG Jiucong, zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)

摘要

摘要: 慢性HBV感染的机制尚未完全阐明，HBV可诱发宿主免疫细胞功能障碍，引起免疫失衡和功能缺陷，这可能是HBV感染慢性化的机制之一。在慢性HBV感染中，自然杀伤(NK)细胞的功能是衰竭的，可能与其细胞表面免疫检查点分子的表达上调相关，阻断免疫检查点可以恢复NK细胞的功能。本文将从HBV病原学、慢性HBV感染机制以及常见免疫检查点在慢性乙型肝炎中对NK细胞功能的影响等方面进行系统综述，旨在为慢性HBV感染的治疗提供新的思路。
- 乙型肝炎, 慢性 /
- 免疫检查点蛋白类 /
- 自然杀伤细胞
Abstract: At present, the mechanism of chronic hepatitis B virus (HBV) infection has not been fully clarified, and HBV can cause immune cell dysfunction, immune imbalance and functional defects in the host, which might be one of the mechanisms of chronic HBV infection. In chronic HBV infection, the functions of natural killer (NK) cells are depleted, which may be associated with the upregulated expression of immune checkpoint molecules on the surface of NK cells, and blocking immune checkpoint molecules can restore the function of NK cells. This article systematically reviews the etiology of HBV, the mechanism of chronic HBV infection, and the effect of common immune checkpoint molecules on functions of NK cells in chronic hepatitis B, so as to provide new ideas for the treatment of chronic HBV infection.
- Hepatitis B, Chronic /
- Immune Checkpoint Proteins /
- Natural Killer Cells

HTML全文

图 1 HBV的生命周期

Figure 1. The life cycle of HBV

下载: 全尺寸图片幻灯片

参考文献(55)

[1]	WHO. Hepatitis B[EB/OL]. (2022-06-24)[2022-10-20]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
[2]	ZHU M, WANG H, LOU T, et al. Current treatment of chronic hepatitis B: Clinical aspects and future directions[J]. Front Microbiol, 2022, 13: 975584. DOI: 10.3389/fmicb.2022.975584.
[3]	MADHUSOODANAN J. Research round-up: hepatitis B[J]. Nature, 2022, 603(7903): S66-S67. DOI: 10.1038/d41586-022-00822-z.
[4]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[5]	RAMJI A, DOUCETTE K, COOPER C, et al. Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue[J]. World J Gastroenterol, 2022, 28(31): 4390-4398. DOI: 10.3748/wjg.v28.i31.4390.
[6]	BUSCA A, KUMAR A. Innate immune responses in hepatitis B virus (HBV) infection[J]. Virol J, 2014, 11: 22. DOI: 10.1186/1743-422X-11-22.
[7]	MAEPA MB, ELY A, KRAMVIS A, et al. Hepatitis B virus research in South Africa[J]. Viruses, 2022, 14(9): 1939. DOI: 10.3390/v14091939.
[8]	SKRLEC I, TALAPKO J. Hepatitis B and circadian rhythm of the liver[J]. World J Gastroenterol, 2022, 28(27): 3282-3296. DOI: 10.3748/wjg.v28.i27.3282.
[9]	TSOUNIS EP, TOURKOCHRISTOU E, MOUZAKI A, et al. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure[J]. World J Gastroenterol, 2021, 27(21): 2727-2757. DOI: 10.3748/wjg.v27.i21.2727.
[10]	BONINO F, COLOMBATTO P, BRUNETTO M R. HBeAg-negative/anti-HBe-positive chronic hepatitis B: a 40-year-old history[J]. Viruses, 2022, 14(8): 1691. DOI: 10.3390/v14081691.
[11]	SEEGER C, MASON WS. Molecular biology of hepatitis B virus infection[J]. Virology, 2015, 479-480: 672-686. DOI: 10.1016/j.virol.2015.02.031.
[12]	JIN X, YAN ZH, LU L, et al. Peripheral immune cells exhaustion and functional impairment in patients with chronic hepatitis B[J]. Front Med (Lausanne), 2021, 8: 759292. DOI: 10.3389/fmed.2021.759292.
[13]	SAJID M, LIU L, SUN C. The dynamic role of NK cells in liver cancers: role in HCC and HBV associated HCC and its therapeutic implications[J]. Front Immunol, 2022, 13: 887186. DOI: 10.3389/fimmu.2022.887186.
[14]	LI HJ, YANG N, MU X, et al. Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Hepatol Int, 2022, 16(6): 1398-1411. DOI: 10.1007/s12072-022-10386-9.
[15]	LI Y, WANG JJ, GAO S, et al. Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B[J]. PLoS One, 2014, 9(2): e86927. DOI: 10.1371/journal.pone.0086927.
[16]	LI X, ZHOU L, GU L, et al. Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment[J]. J Transl Med, 2017, 15(1): 220. DOI: 10.1186/s12967-017-1318-1.
[17]	MONDELLI MU, VARCHETTA S, OLIVIERO B. Natural killer cells in viral hepatitis: facts and controversies[J]. Eur J Clin Invest, 2010, 40(9): 851-863. DOI: 10.1111/j.1365-2362.2010.02332.x.
[18]	SUN C, SUN HY, XIAO WH, et al. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy[J]. Acta Pharmacol Sin, 2015, 36(10): 1191-1199. DOI: 10.1038/aps.2015.41.
[19]	CHEN Y, TIAN Z. HBV-induced immune imbalance in the development of HCC[J]. Front Immunol, 2019, 10: 2048. DOI: 10.3389/fimmu.2019.02048.
[20]	YU L, LIU X, WANG X, et al. TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Oncoimmunology, 2021, 10(1): 1942673. DOI: 10.1080/2162402X.2021.1942673.
[21]	WANG X, XIONG H, NING Z. Implications of NKG2A in immunity and immune-mediated diseases[J]. Front Immunol, 2022, 13: 960852. DOI: 10.3389/fimmu.2022.960852.
[22]	LI F, WEI H, WEI H, et al. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice[J]. Gastroenterology, 2013, 144(2): 392-401. DOI: 10.1053/j.gastro.2012.10.039.
[23]	MA Q, DONG X, LIU S, et al. Hepatitis B e antigen induces NKG2A+ natural killer cell dysfunction via regulatory T cell-derived interleukin 10 in chronic hepatitis B virus Infection[J]. Front Cell Dev Biol, 2020, 8: 421. DOI: 10.3389/fcell.2020.00421.
[24]	PERUZZI G, MASILAMANI M, BORREGO F, et al. Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2A[J]. Immunol Res, 2009, 43(1-3): 210-222. DOI: 10.1007/s12026-008-8072-7.
[25]	LI PW, SHEN YQ. Effect of immune-checkpoint molecules on T-cell function in chronic infection with the HBV[J]. J Virol, 2021, 37(2): 465-470. DOI: 10.13242/j.cnki.bingduxuebao.003914. 李鹏尉, 沈宇清. 免疫检查点分子在慢性HBV感染中对T细胞功能影响的研究进展[J]. 病毒学报, 2021, 37(2): 465-470. DOI: 10.13242/j.cnki.bingduxuebao.003914.
[26]	WANG Y, ZHANG H, LIU C, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts[J]. J Hematol Oncol, 2022, 15(1): 111. DOI: 10.1186/s13045-022-01325-0.
[27]	LI H, ZHAI N, WANG Z, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection[J]. Gut, 2018, 67(11): 2035-2044. DOI: 10.1136/gutjnl-2017-314098.
[28]	LI F. Correlation between the expression of PD-1/PD-L1 on NK cells and HBV infection[D]. Hengyang: University of South China, 2020. 李芬. NK细胞上PD-1/PD-L1表达与HBV感染相关性研究[D]. 衡阳: 南华大学, 2020.
[29]	QUATRINI L, MARIOTTI F R, MUNARI E, et al. The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy[J]. Cancers (Basel), 2020, 12(11): 3285. DOI: 10.3390/cancers12113285.
[30]	BAI R, CUI J. Burgeoning exploration of the role of natural killer cells in Anti-PD-1/PD-L1 therapy[J]. Front Immunol, 2022, 13: 886931. DOI: 10.3389/fimmu.2022.886931.
[31]	WOLF Y, ANDERSON AC, KUCHROO VK. TIM3 comes of age as an inhibitory receptor[J]. Nat Rev Immunol, 2020, 20(3): 173-185. DOI: 10.1038/s41577-019-0224-6.
[32]	CAI X, ZHAN H, YE Y, et al. Current progress and future perspectives of immune checkpoint in cancer and infectious diseases[J]. Front Genet, 2021, 12: 785153. DOI: 10.3389/fgene.2021.785153.
[33]	LIU Y, GAO LF, LIANG XH, et al. Role of Tim-3 in hepatitis B virus infection: An overview[J]. World J Gastroenterol, 2016, 22(7): 2294-2303. DOI: 10.3748/wjg.v22.i7.2294.
[34]	JU Y, HOU N, MENG J, et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B[J]. J Hepatol, 2010, 52(3): 322-329. DOI: 10.1016/j.jhep.2009.12.005.
[35]	YANG X, LI M, QIN X, et al. Photophosphatidylserine guides natural killer cell photoimmunotherapy via tim-3[J]. J Am Chem Soc, 2022, 144(9): 3863-3874. DOI: 10.1021/jacs.1c11498.
[36]	TAN S, XU Y, WANG Z, et al. Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling[J]. Cancer Res, 2020, 80(5): 1130-1142. DOI: 10.1158/0008-5472.CAN-19-2332.
[37]	JIAO J, JIAO D, YANG F, et al. Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma[J]. Aging (Albany NY), 2022, 14(4): 1879-1890. DOI: 10.18632/aging.203909.
[38]	LI WQ, YU X, HOU ZH, et al. HBV impairs the function of NK cells by upregulating Galectin-9 expression on hepatocytes[J]. Current Immunology, 2014, 34(6): 471-477. https://www.cnki.com.cn/Article/CJFDTOTAL-SHMY201406006.htm 李卫群, 于馨, 侯召华, 等. HBV通过上调肝细胞表面Galectin-9的表达抑制NK细胞的功能[J]. 现代免疫学, 2014, 34(6): 471-477. https://www.cnki.com.cn/Article/CJFDTOTAL-SHMY201406006.htm
[39]	LI HR, ZHANG FQ, ZHANG ZC, et al. Research progress on mechanism of immunosuppressive receptor TIGIT in pathogen infection[J]. Chin J Immunol, 2022, 38(5): 632-637. DOI: 10.3969/j.issn.1000-484X.2022.05.022. 李浩然, 张富强, 张振超, 等. 免疫抑制性受体TIGIT在病原体感染中的作用机制研究进展[J]. 中国免疫学杂志, 2022, 38(5): 632-637. DOI: 10.3969/j.issn.1000-484X.2022.05.022.
[40]	JEONG BS, NAM H, LEE J, et al. Structural and functional characterization of a monoclonal antibody blocking TIGIT[J]. MAbs, 2022, 14(1): 2013750. DOI: 10.1080/19420862.2021.2013750.
[41]	YAO F, YIN X. Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects[J]. J Clin Hepatol, 2022, 38(11): 2632-2635. DOI: 10.3969/j.issn.1001-5256.2022.11.039. 姚帆, 殷欣. 免疫检查点TIGIT/CD155对原发性肝癌免疫微环境的调控作用及应用展望[J]. 临床肝胆病杂志, 2022, 38(11): 2632-2635. DOI: 10.3969/j.issn.1001-5256.2022.11.039.
[42]	YEO J, KO M, LEE DH, et al. TIGIT/CD226 axis regulates anti-tumor immunity[J]. Pharmaceuticals (Basel), 2021, 14(3): 200. DOI: 10.3390/ph14030200.
[43]	MOLFETTA R, ZITTI B, LECCE M, et al. CD155: a multi-functional molecule in tumor progression[J]. Int J Mol Sci, 2020, 21(3): 922. DOI: 10.3390/ijms21030922.
[44]	KUZEVANOVA A, APANOVICH N, MANSORUNOV D, et al. The features of checkpoint receptor-ligand interaction in cancer and the therapeutic effectiveness of their inhibition[J]. Biomedicines, 2022, 10(9): 2081. DOI: 10.3390/biomedicines10092081.
[45]	ANNESE T, TAMMA R, RIBATTI D. Update in TIGIT immune-checkpoint role in cancer[J]. Front Oncol, 2022, 12: 871085. DOI: 10.3389/fonc.2022.871085.
[46]	LU Y, SUN R, TIAN ZG, et al. Study on role of TIGIT in HBV immunotherapy[J]. Chin J Immunol, 2022, 38(2): 129-134. DOI: 10.3969/j.issn.1000-484X.2022.02.001. 卢杨, 孙汭, 田志刚, 等. TIGIT分子在HBV免疫治疗中的作用探究[J]. 中国免疫学杂志, 2022, 38(2): 129-134. DOI: 10.3969/j.issn.1000-484X.2022.02.001.
[47]	KHAN M, AROOJ S, WANG H. NK cell-based immune checkpoint inhibition[J]. Front Immunol, 2020, 11: 167. DOI: 10.3389/fimmu.2020.00167.
[48]	LI YL, ZHANG QF, YIN WW, et al. Reduced frequency of natural killer cell on siglec-7(+) is associated with progression of hepatitis B virus-related cirrhosis[J]. Chin J Hepatol, 2018, 26(6): 420-425. DOI: 10.3760/cma.j.issn.1007-3418.2018.06.006. 李彦霖, 张琼方, 殷文伟, 等. Siglec-7⁺自然杀伤细胞频数下降与乙型肝炎病毒相关肝硬化疾病进展相关[J]. 中华肝脏病杂志, 2018, 26(6): 420-425. DOI: 10.3760/cma.j.issn.1007-3418.2018.06.006.
[49]	ZHAO D, JIANG X, XU Y, et al. Decreased siglec-9 expression on natural killer cell subset associated with persistent HBV replication[J]. Front Immunol, 2018, 9: 1124. DOI: 10.3389/fimmu.2018.01124.
[50]	ALFARRA H, WEIR J, GRIEVE S, et al. Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy[J]. Front Immunol, 2020, 11: 575609. DOI: 10.3389/fimmu.2020.575609.
[51]	NARAYANAN S, AHL PJ, BIJIN VA, et al. LAG3 is a central regulator of NK cell cytokine production[J]. bioRxiv, 2020. DOI: 10.1101/2020.01.31.928200.[Olineaheadofprint]
[52]	WANG J, HOU H, MAO L, et al. TIGIT signaling pathway regulates natural killer cell function in chronic hepatitis B virus infection[J]. Front Med (Lausanne), 2021, 8: 816474. DOI: 10.3389/fmed.2021.816474.
[53]	REVILL PA, CHISARI FV, BLOCK JM, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019, 4(7): 545-558. DOI: 10.1016/S2468-1253(19)30119-0.
[54]	INC AP. Ascletis announces results of the phase Ⅱa trial of ASC22 (Envafolimab) in patients with chronic hepatitis B to be presented in oral parallel session at the liver meeting^Ⓡ 2021 by American Association for the Study of Liver Diseases[EB/OL]. (2021-10-11)[2022-10-20]. https://www.prnewswire.com/news-releases/ascletis-announces-results-of-the-phase-iia-trial-of-asc22-envafolimab-in-patients-with-chronic-hepatitis-b-to-be-presented-in-oral-parallel-session-at-the-liver-meeting-2021-by-american-association-for-the-study-of-liver-disea-301396930.html.
[55]	MARKHAM A. Envafolimab: first approval[J]. Drugs, 2022, 82(2): 235-240. DOI: 10.1007/s40265-022-01671-w.

施引文献

资源附件(0)

访问统计

本文二维码

图(1)

计量

文章访问数: 288
HTML全文浏览量: 75
PDF下载量: 44
被引次数: 0

用微信扫码二维码

分享至好友和朋友圈

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

免疫检查点对慢性HBV感染者自然杀伤细胞功能的影响

DOI: 10.3969/j.issn.1001-5256.2023.08.025

通信作者:
郑晓凤，zhengxf19892013@126.com (ORCID: 0009-0002-9660-1224)

张久聪，zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)

计量

Effect of immune checkpoint molecules on the function of natural killer cells in patients with chronic hepatitis B virus infection

Corresponding author: ZHENG Xiaofeng, zhengxf19892013@126.com (ORCID: 0009-0002-9660-1224); ZHANG Jiucong, zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)

计量

目录

留言板

免疫检查点对慢性HBV感染者自然杀伤细胞功能的影响

DOI: 10.3969/j.issn.1001-5256.2023.08.025

通信作者: 郑晓凤，zhengxf19892013@126.com (ORCID: 0009-0002-9660-1224) 张久聪，zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)

计量

出版历程

Effect of immune checkpoint molecules on the function of natural killer cells in patients with chronic hepatitis B virus infection

Corresponding author: ZHENG Xiaofeng, zhengxf19892013@126.com (ORCID: 0009-0002-9660-1224); ZHANG Jiucong, zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)

计量

出版历程

目录

关于本刊

投稿指南

在线期刊

肝胆学院

指南共识

通信作者:
郑晓凤，zhengxf19892013@126.com (ORCID: 0009-0002-9660-1224)

张久聪，zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)